Professional Documents
Culture Documents
• Cost-minimization analysis
Cost-minimization (CMA)
is the simplest of the pharmacoeconomics tools and is applied
when comparing two drugs of equal efficacy and equal
tolerability.
• Cost-effectiveness analysis
On the plus side, CUA allows comparison across different health programs
and policies by using a common unit of measure (money/QALYs gained). CUA
provides a more complete analysis of total benefits than simple cost-benefit
analysis does. This is because CUA takes into account the quality of life that
an individual has, while CBA does not.
However, in CUA societal benefits and costs are often not taken into
account. Furthermore, some economists believe that measuring QALYs is
more difficult than measuring the monetary value of life through through
health improvements, as is done with CBA. This is because in CUA you need
to measure the health improvement effects for every remaining year of life
after the program is initiated. While for CBA we have an approximate value
of life ($2 million is one of the estimates), we do not have a QALY estimate
for nearly every medical treatment or disease.
In addition, some people believe that life is priceless and there are ethical
problems with placing a value on human life.